NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route (Descending) | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
53150-0314-10 | 53150-0314 | Doxorubicin Hydrochloride | Doxorubicin Hydrochloride | 20.0 mg/10mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | April 30, 2013 | Dec. 31, 2017 | No Longer Used |
53150-0315-01 | 53150-0315 | Doxorubicin Hydrochloride | Doxorubicin Hydrochloride | 50.0 mg/25mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | April 30, 2013 | Dec. 31, 2017 | No Longer Used |
53150-0317-01 | 53150-0317 | Doxorubicin Hydrochloride | Doxorubicin Hydrochloride | 200.0 mg/100mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | April 30, 2013 | Dec. 31, 2017 | No Longer Used |
53150-0320-01 | 53150-0320 | Doxorubicin Hydrochloride | Doxorubicin Hydrochloride | 10.0 mg/5mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | April 30, 2013 | Dec. 31, 2017 | No Longer Used |
53150-0320-10 | 53150-0320 | Doxorubicin Hydrochloride | Doxorubicin Hydrochloride | 10.0 mg/5mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | April 30, 2013 | Dec. 31, 2017 | No Longer Used |
54868-0173-00 | 54868-0173 | methotrexate | Methotrexate | 25.0 mg/mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intra-arterial, Intramuscular, Intrathecal, Intravenous | March 26, 2003 | In Use | |
55292-0911-51 | 55292-0911 | Mechlorethamine hydrochloride | Mustargen | 10.0 mg/10mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intracavitary, Intravenous | March 15, 1949 | March 31, 2019 | No Longer Used |
44087-3535-01 | 44087-3535 | Avelumab | Bavencio | 20.0 mg/mL | Immunotherapy | Checkpoint Inhibitor | PD-L1 | Intravenous | March 23, 2017 | In Use | |
50742-0404-01 | 50742-0404 | Topotecan | Topotecan | 4.0 mg/4mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Dec. 7, 2016 | In Use | |
50742-0423-10 | 50742-0423 | FLUOROURACIL | FLUOROURACIL | 50.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Dec. 21, 2019 | In Use | |
50742-0428-02 | 50742-0428 | Docetaxel Anhydrous | Docetaxel | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Sept. 7, 2017 | April 30, 2021 | In Use |
50742-0420-01 | 50742-0420 | Vinorelbine | Vinorelbine | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Vinca Alkaloid | Intravenous | Aug. 8, 2019 | In Use | |
50742-0427-05 | 50742-0427 | Vinorelbine | Vinorelbine | 50.0 mg/5mL | Chemotherapy | Antimitotic Agent | Vinca Alkaloid | Intravenous | Aug. 8, 2019 | In Use | |
50742-0445-05 | 50742-0445 | Carboplatin | Carboplatin | 50.0 mg/5mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | May 6, 2017 | Feb. 12, 2018 | In Use |
50742-0446-15 | 50742-0446 | Carboplatin | Carboplatin | 150.0 mg/15mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | May 6, 2017 | Feb. 12, 2018 | In Use |
50742-0481-20 | 50742-0481 | FLUOROURACIL | FLUOROURACIL | 50.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Dec. 21, 2019 | In Use | |
50742-0482-50 | 50742-0482 | fluorouracil | FLUOROURACIL | 2.5 g/50mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Dec. 21, 2019 | In Use | |
50742-0483-99 | 50742-0483 | fluorouracil | FLUOROURACIL | 5.0 g/100mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | Dec. 21, 2019 | In Use | |
50742-0512-20 | 50742-0512 | Clofarabine | Clofarabine | 1.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Sept. 27, 2018 | In Use | |
50742-0525-07 | 50742-0525 | arsenic trioxide | ARSENIC TRIOXIDE | 2.0 mg/mL | Chemotherapy | Miscellaneous Agent | PML/RARa | Intravenous | Jan. 27, 2021 | In Use | |
72187-0401-01 | 72187-0401 | Tagraxofusp | Elzonris | 1000.0 ug/mL | Immunotherapy | Fusion Protein | IL3/ CD123 | Intravenous | Jan. 18, 2019 | In Use | |
73380-4700-01 | 73380-4700 | MOXETUMOMAB PASUDOTOX | LUMOXITI | 1.0 mg/mL | Immunotherapy | Drug Antibody Conjugate | CD22 | Intravenous | May 15, 2020 | In Use | |
51144-0003-01 | 51144-0003 | Tisotumab vedotin | TIVDAK | 40.0 mg/4mL | Immunotherapy | Drug Antibody Conjugate | Tissue factor | Intravenous | Sept. 20, 2021 | In Use | |
57277-0107-45 | 57277-0107 | carboplatin Injection | Carboplatin | 450.0 mg/5mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Sept. 29, 2016 | In Use | |
57884-3021-00 | 57884-3021 | Docetaxel | Docetaxel | 40.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Feb. 15, 2017 | Oct. 29, 2021 | In Use |
Found 10,000 results in 11 milliseconds — Export these results